ImmuPharma Shares Rise on Positive Guidance From US FDA for P140
By Kyle Morris
Shares in ImmuPharma rose 11% on Thursday after the company said it received positive guidance from the U.S. Food and Drug Administration that supports an Investigational New Drug application and a phase 2/3 adaptive clinical trial of the P140 platform for patients with chronic idiopathic demyelinating polyneuropathy.
Shares at 0850 GMT were up 0.33 pence at 3.40 pence.
The company said the FDA feedback recognised that P140 is suitable to be studied in another disease indication in addition to systemic lupus erythematosus, which supports P140 across several auto-immune/inflammatory diseases.
An IND application will now be prepared for submission to the FDA.
An application for Orphan Drug status for CIDP will be also submitted in parallel to the full IND application.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
May 18, 2023 05:23 ET (09:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?